ISLAMABAD: Health authorities on Tuesday denied reports of a widespread insulin shortage in Pakistan, saying only one brand was unavailable because of international supply constraints.
The clarification, first reported by Dawn, came after reports of a shortage across the country emerged on social media. The health ministry and the Drug Regulatory Authority of Pakistan (Drap) maintained that alternatives for the unavailable brand remained available in the market.
“Insulin glulisine (Apidra, Sanofi) is currently unavailable due to international supply constraints. Alternate rapid-acting analogues within the same pharmacological class, specifically insulin aspart (NovoRapid, Novo Nordisk) and insulin lispro (Humalog, Eli Lilly), are readily available nationwide,” ministry spokesperson Sajid Shah said.
“All other primary insulin classes remain fully accessible across Pakistan,” he added.
What patients should know
The spokesperson explained that insulin analogues, one of the two categories of medically approved insulin, include rapid-acting, long-acting and premixed formulations. The other category, human insulin, includes short-acting and intermediate-acting formulations.
He said patients who have been prescribed Apidra “should consult their attending healthcare provider prior to modifying their regimen”.
“Any transition to an alternative insulin formulation requires precise dose titration and tailored monitoring to maintain optimal glycaemic control,” he said.
For the millions of Pakistanis living with diabetes, the message is reassuring but comes with a caution: do not switch brands on your own. Dose strengths and absorption profiles differ between insulin analogues, so a doctor should supervise any change.
A history of shortage alarms
The denial lands against a backdrop of repeated medicine-shortage warnings. In August 2025, the Pakistan Medical Association (PMA) raised the alarm over what it called an “unprecedented” and severe shortage of essential medicines across the country, warning that the crisis threatened the lives of millions of patients. The association said at least 80 important medicines were unavailable, with 25 having no substitutes — including life-saving drugs for diabetes, cancer, Alzheimer’s, Parkinson’s, heart disease and psychiatric disorders.
In March 2026, the PMA cautioned about a severe shortage of essential paediatric tuberculosis as well as cancer medications, warning that the humanitarian crisis was getting worse with each passing day and calling for immediate intervention.
That history explains why social-media reports of an insulin shortage spread quickly, and why the ministry moved fast to rebut them. The authorities’ position is that this time the gap is limited to a single imported brand with documented international supply problems — not a systemic failure.
Why the insulin shortage in Pakistan debate matters
Insulin is not optional medication. For people with type 1 diabetes, and many with advanced type 2 diabetes, a missed dose can be life-threatening within hours. Pakistan has one of the highest diabetes rates in the world, which is why any hint of an insulin shortage triggers panic among patients and pharmacists alike.
The ministry’s assurance rests on two claims: that the unavailable product is only one brand (Sanofi’s Apidra), and that two equivalent rapid-acting analogues are “readily available nationwide”. Patients and pharmacies will now test both claims in practice. If NovoRapid or Humalog start running thin in smaller cities, the ministry will face fresh questions.
For now, the official line is clear: there is no nationwide insulin shortage in Pakistan. But the PMA’s warnings from last year and this spring are a reminder that the country’s medicine supply chain has been fragile, and patients have reason to stay alert.
Frequently asked questions
Is there an insulin shortage in Pakistan?
Health authorities say no. They deny reports of a nationwide shortage, saying only Sanofi’s insulin glulisine (Apidra) is unavailable due to international supply constraints.
Which insulin brands are available?
The ministry says insulin aspart (NovoRapid, Novo Nordisk) and insulin lispro (Humalog, Eli Lilly) are readily available nationwide, along with all other primary insulin classes.
Should patients switch brands themselves?
No. The ministry says patients prescribed Apidra should consult their doctor before changing, since switching formulations needs precise dose adjustment and monitoring.
